Resident Evil Wiki
Resident Evil Wiki
(Interwiki Link)
No edit summary
Line 1: Line 1:
  +
:{{DISPLAYTITLE|BSAA}}
 
:Following the annihilation of [[Raccoon City]], [[Umbrella]]
 
:Following the annihilation of [[Raccoon City]], [[Umbrella]]
 
:was hit hard with multiple lawsuits for their
 
:was hit hard with multiple lawsuits for their

Revision as of 14:30, 28 June 2012

Following the annihilation of Raccoon City, Umbrella
was hit hard with multiple lawsuits for their
involvement in the incident. But there was an
organization that was hit even harder by the fallout
of that incident: the Global Pharmaceutical
Consortium, an organization comprised of
pharmaceutical companies from around the world.


Umbrella's development of and experimentation with
Bio Organic Weapons (B.O.W.), along with the sale of
those weapons on the black market, caused people to
distrust the Global Pharmaceutical Consortium, and
the fact that Umbrella was an executive board member
only deepened their misgivings.


If things had ended there, the consortium may have
just escaped with a tarnished reputation. But in
today's world, medicine is an integral part of almost
all medical procedures. The public is also quite
informed when it comes to which medications are
trusted and which are not. If the population looses
trust in the pharmaceutical company responsible for
creating certain medications, it can quickly bankrupt
said company.


The Umbrella trials took a turn for the worse for the
consortium when prosecutors presented evidence that
incriminated many other pharmaceutical companies.


Prosecutors showed that Umbrella acquired medicines
and techniques developed by other companies and
employed them in their own bioweapons research. They
commissioned each of the respective companies to only
partially develop certain medications so that they
could not be traced to what was ultimately being
developed. The responsible companies thus
unwittingly contributed to the development of
bioweapons.


Until this development in the case, the consortium
looked at the lawsuits as Umbrella's problem. Now the
problem was thrust into their laps as well.


The companies that were linked to Umbrella faced the
possibility of sharing blame for the deaths of
hundreds of thousands of innocent people, and if
Umbrella lost the lawsuits, they would face
bankruptcy as well. Even if Umbrella was found not
guilty of any wrongdoing, the negative publicity
would not only be disastrous for sales, but the
governments of the world would revoke the companies'
permits to sell their products.


Not having permission to distribute their products
worldwide would effectively dismantle their
businesses.


The pharmaceutical companies realized they had no
choice but to take drastic measures to counter their
dismal prospects.


The consortium decided to strike a deal with the
prosecutors. They would put all their efforts into
assisting with the case against Umbrella, even to the
point of turning over any internal company
documentation. The prosecutors in the case, being
obsessed with seeing Umbrella fall, agreed to accept
the help of the consortium's companies, and in return
they would not pursue legal action against them.


In 2003, Umbrella was found guilty on all charges.
With its fall, the scandal that rocked the
pharmaceutical industry to its core could finally be
put to rest.


But Umbrella's dismantlement led to an unforeseen
situation.


In the fallout of Umbrella's collapse, B.O.W.s
began to show up on the black market. The
weapons wound up in the hands of terrorists, guerrilla
fighters, and unstable state governments. Soon the
threat of these B.O.W.s began to be felt around the
world.


Faced with a new Umbrella-like crisis, the Global
Pharmaceutical Consortium knew they would have to
take immediate action.


It was then that the Bioterrorism Security Assessment
Alliance (BSAA) was formed to fight threats from
B.O.W.s.


Upon its initial foundation, only eleven elite
individuals were made part of the BSAA. Their job was
limited to that of observers to armies and police
units around the world that conducted counter-
bioterrorism operations. Unfortunately, the world's
bioterrorism problem was much bigger than anyone had
anticipated, and so a new course of action was
required to handle the problem.


To that end, consideration was given to creating a
team that could react instantly to threats, but the
BSAA was still only a civilian-led organization.
They could not operate freely in sovereign nations,
and thus were unable to conduct investigations,
make pertinent arrests, or even use force when the
situation dictated it. It was clear now that the
threat of bioterrorism was now the entire world's
problem, and something would have to be done.


The BSAA was then reformed under the U.N.'s
jurisdiction.


As a U.N.-controlled special forces team, the BSAA's
acceptance by the U.N.'s member states was taken as a
given.


The truth of the matter was that only 70 percent of
the member states would approve of BSAA activities on
their soil, and the remainder of the states would only
approve BSAA activities in their countries on a
conditional basis.


That is how the current incarnation of the BSAA was
formed.


The BSAA's headquarters was located in England, but
any further details of the location were not released
to the public. Since a BSAA team had to be able to be
deployed within 12 hours, it was assumed that they
were located near airport hub or an air force base.
Some courses claimed that the BSAA had bases in the
area under their jurisdiction.


The following is a list of areas under the
jurisdiction of their respective BSAA branches.
European Headquarters: Europe and western Russia
Middle East Branch: The Middle of East and part of
Africa
North American Branch: The entire North American
continent (Chris Redfield and Jill Valentine are stationed here)
South American Branch: The entire South American
continent
West African Branch: The western part of the African
continent (Sheva Alomar is stationed here)
East African Branch: The eastern part of the African
continent
Far East Branch: Eastern Russia and the countries east
of India
Oceanian Branch: Australia is the center of operations
of Oceania
(Antarctica, where Umbrella's Antarctic Base was
located, falls under the jurisdiction of the Oceanian
Branch.)


Each BSAA branch had a considerable number of people
on their tactical teams, most of them coming from
police special forces and militaries around the world.


The support staff for the teams was also quite large,
and they came mainly from government organizations
in different countries. There were many groups of
experts on the staff that provided technical, medical,
physical, and mental support to the teams.


The BSAA deployment teams were divided into two
groups.


The first group was the Special Operations Unit (SOU).
The SOU were sanctioned to infiltrate an area, engage
in combat, and subdue offenders. Teams were usually
comprised of 12 members, and each team was divided
into three four-man cells.


A special feature of the SOU is the flexibility of its
personnel during operations. In order to match the
scale of an operation, cells from other teams are
brought in on a regular basis. For one specific joint
operation, there were 70 elite members working
together.


Dan DeChant is currently the leader of Alpha Team for
this operation. The team is comprised of his own
standard team along with cells from other teams. (The
designation Alpha Team will only be used for this
operation.)


Reports indicate that because unknown B.O.W.s are
involved, the efficacy of the tactical team's methods
for handling them may be low, and consideration has
to be given to the strong points that raise their
efficacy.


Another key part of the BSAA is the Special
Operations Agent (SOA). Usually they are referred to
as just "agents", and unlike the SOU, agents work
alone. The agents are primarily involved in
investigations and espionage activities, and as
such, they are considered the eyes and ears for the
BSAA. During certain operations, it may become
difficult for tactical teams to penetrate to the
front, so it is up to the agents to carry out the
missions.


During those types of missions, a two-man cell is the
basic deployment unit required to carry out the
mission.


Sometimes agents must go beyond the jurisdiction of a
BSAA branch to carry out their missions. Many of them
are dispatched to areas with unlawful activities. This
mission sees agent Chris Redfield in that role.


Agents who work alone are highly capable, and they
rank higher than SOU members; however, agents are
not chosen so much for their abilities or technical
prowess, but for the psychological state and aptitude
in handling situations. In actual skills and
abilities, they may be outperformed by SOU members.


The BSAA is a public organization with an
international staff, but owing to the logistics of
running such an organization, it is a well-known
fact that most of their funding comes from the Global
Pharmaceutical Consortium.


While this relationship has been the target of much
criticism, the consortium's funding removes the
financial burden from participatory nations, and as
such, any motivation to change the situation and
incur unwanted expenses. As for the consortium, their
sponsorship acts as much needed industry-wide PR
service. So far this partnership has been beneficial
to all parties involved.


On a final note, the eleven members who were part of
the BSAA from the beginning are highly respected
within the organization, and are known as the
Original Eleven. The name comes from the Original
Seven, who were the seven astronauts selects for
Project Mercury.


Two of these Original Eleven are Chris Redfield and Jill Valentine. A
number of other members of the Original Eleven also
work alongside many of the tactical teams.

Template:RE5 Files